R. Nikolaiev, M. Vivcharyk, S. Levchenko, S. Chernykh, N. Obernikhina, Z. Tkachuk
{"title":"Conformational changes of secondary and tertiary structures of interferon under the influence of oligoribonucleotides-based drugs","authors":"R. Nikolaiev, M. Vivcharyk, S. Levchenko, S. Chernykh, N. Obernikhina, Z. Tkachuk","doi":"10.3390/ecmc-4-05629","DOIUrl":"https://doi.org/10.3390/ecmc-4-05629","url":null,"abstract":"","PeriodicalId":20450,"journal":{"name":"Proceedings of 4th International Electronic Conference on Medicinal Chemistry","volume":"26 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-11-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"82554775","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
G. Diamond, L. Ryan, R. Parveen, A. Hise, K. Freeman, R. Scott
Systemic fungal infections are increasingly common, especially in immune compromised patients. Even with newly developed drugs, there remain issues of limited spectrum, side effects, and the development of resistance. Host defense peptides (HDPs) have been examined recently for their utility as therapeutic antifungals, especially due to the low levels of resistance that develop. Unfortunately, the peptides exhibit poor pharmacologic properties in vivo. We have demonstrated the potent activity of nonpeptidic compounds that mimic HDPs in both structure and function against clinical strains of Candida albicans associated with oral and invasive candidiasis in mouse models. However, to test numerous compounds in vivo requires large numbers of mice, with multiple time points, and requires immunosuppression of the mice using cyclophosphamide, which can influence pharmacological parameters. We have identified a strain of mouse that develops invasive candidiasis without the need for immunosuppressive drugs. When we infect these mice with a strain of C. albicans that constitutively expresses Red Fluorescent Protein, we can quantify the infection in real time by in vivo imaging. We can further observe the reduction in fluorescence in infected mice after treatment with an HDP mimetic. Together our results demonstrate a novel in vivo method for screening new antifungal drugs.
{"title":"In vivo imaging of the activity of host defense peptide mimetics in a mouse model of invasive candidiasis","authors":"G. Diamond, L. Ryan, R. Parveen, A. Hise, K. Freeman, R. Scott","doi":"10.3390/ecmc-4-05628","DOIUrl":"https://doi.org/10.3390/ecmc-4-05628","url":null,"abstract":"Systemic fungal infections are increasingly common, especially in immune compromised patients. Even with newly developed drugs, there remain issues of limited spectrum, side effects, and the development of resistance. Host defense peptides (HDPs) have been examined recently for their utility as therapeutic antifungals, especially due to the low levels of resistance that develop. Unfortunately, the peptides exhibit poor pharmacologic properties in vivo. We have demonstrated the potent activity of nonpeptidic compounds that mimic HDPs in both structure and function against clinical strains of Candida albicans associated with oral and invasive candidiasis in mouse models. However, to test numerous compounds in vivo requires large numbers of mice, with multiple time points, and requires immunosuppression of the mice using cyclophosphamide, which can influence pharmacological parameters. We have identified a strain of mouse that develops invasive candidiasis without the need for immunosuppressive drugs. When we infect these mice with a strain of C. albicans that constitutively expresses Red Fluorescent Protein, we can quantify the infection in real time by in vivo imaging. We can further observe the reduction in fluorescence in infected mice after treatment with an HDP mimetic. Together our results demonstrate a novel in vivo method for screening new antifungal drugs.","PeriodicalId":20450,"journal":{"name":"Proceedings of 4th International Electronic Conference on Medicinal Chemistry","volume":"46 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-11-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"87507111","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Jorge Jonathan Nué Martinez, C. Millan, G. Ebiloma, H. D. Koning, L. Campos, C. Dardonville
The parasite Trypanosoma brucei, ethiologic agent of human African trypanosomiasis (i.e. sleeping sickness), contains a kinetoplast with the mitochondrial DNA (kDNA) comprising of >70 % AT base pairs. Hence, DNA minor groove binding molecules have been investigated as antitrypanosomal agents. Diphenyl-based bis(2-iminoimidazolidines) are promising DNA minor groove binders that are curative in mouse models of stage 1 trypanosomiasis but devoid of activity in the late(CNS)-stage disease, possibly due to poor brain penetration caused by their dicationic nature. As a strategy to reduce the pKa of the basic 2-iminoimidazolidine groups, halogen atoms (R1 = Cl, F) were introduced in the structure of lead compound 1 and the pKa of the new compounds was determined . A reduction of 1–2 pKa units for the imidazolidine group linked to the substituted phenyl ring was observed. In vitro activities (EC50) against wild type and resistant strains of T. b. brucei were in the submicromolar range with four compounds being more active and selective than 1 (SI > 340).1 The chloro-substituted derivative 5a, which was curative in vivo in a mouse model of stage 1 infection by T. b. rhodesiense, appeared as a new promising lead compound.2 Mechanistic studies were performed to identify the cellular target of these dicationic compounds. Altogether, our results show that 1 and 5a share the same mechanism of action against T. brucei, acting specifically on the integrity of the kinetoplast by altering the structure and replication of kDNA.2
{"title":"pKa modulation of a bis(2-aminoimidazoline) DNA minor groove binder that targets the kinetoplast of Trypanosoma brucei","authors":"Jorge Jonathan Nué Martinez, C. Millan, G. Ebiloma, H. D. Koning, L. Campos, C. Dardonville","doi":"10.3390/ecmc-4-05626","DOIUrl":"https://doi.org/10.3390/ecmc-4-05626","url":null,"abstract":"The parasite Trypanosoma brucei, ethiologic agent of human African trypanosomiasis (i.e. sleeping sickness), contains a kinetoplast with the mitochondrial DNA (kDNA) comprising of >70 % AT base pairs. Hence, DNA minor groove binding molecules have been investigated as antitrypanosomal agents. Diphenyl-based bis(2-iminoimidazolidines) are promising DNA minor groove binders that are curative in mouse models of stage 1 trypanosomiasis but devoid of activity in the late(CNS)-stage disease, possibly due to poor brain penetration caused by their dicationic nature. \u0000As a strategy to reduce the pKa of the basic 2-iminoimidazolidine groups, halogen atoms (R1 = Cl, F) were introduced in the structure of lead compound 1 and the pKa of the new compounds was determined . A reduction of 1–2 pKa units for the imidazolidine group linked to the substituted phenyl ring was observed. In vitro activities (EC50) against wild type and resistant strains of T. b. brucei were in the submicromolar range with four compounds being more active and selective than 1 (SI > 340).1 The chloro-substituted derivative 5a, which was curative in vivo in a mouse model of stage 1 infection by T. b. rhodesiense, appeared as a new promising lead compound.2 \u0000Mechanistic studies were performed to identify the cellular target of these dicationic compounds. Altogether, our results show that 1 and 5a share the same mechanism of action against T. brucei, acting specifically on the integrity of the kinetoplast by altering the structure and replication of kDNA.2","PeriodicalId":20450,"journal":{"name":"Proceedings of 4th International Electronic Conference on Medicinal Chemistry","volume":"284 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-11-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"74944490","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Bazureau Jean Pierre, C. D. Dago, L. Voli, T. Roisnel, C. Brigaudeau, Y. Bekro, Janat Mamybékova, O. Mignen
The racemic synthesis in four steps of pyrazole SKF-96365 analogues without substituent (CF3 group) on the pyrazole platform was realized in moderate to good yields. The separation of (±) hydroxyl enantiomers 4 was developed successfully using the method of "half-concentration" with commercial (+)-(1S)- and (-)-(1R)-10-camphorsulfonic acid (CSA) followed by neutralization of diastereomers with MeONa in dry MeOH solution. With the pure enantiomers (-)-(1S)-4b and (+)-(1R)-4b, initial attempts to obtain the crystallized (-)-(1S)-7d and (+)-(1R)-7d after treatment of intermediate 6d with a solution of 1M HCl (for precipitation of hydrochloride salt 7d) failed. We have also investigated the effects of compounds 7(a-d) on endoplasmic reticulum (ER) Ca2+ and SOCE on PLP-B lymphocyte cell line and compound 7d was identified as a better SOCE inhibitor than SKF-96365. This preliminary SAR study showed that the MeO group in para-position of the phenethyl-1H-pyrazolium skeleton or for the Cbeta-phenylpropoxy side chain of 7 influenced the SOCE activity.
{"title":"A Practical Access to New Pyrazole SKF-96365 Analogues as Potential Store-Operated Calcium Entry (SOCE) Inhibitors","authors":"Bazureau Jean Pierre, C. D. Dago, L. Voli, T. Roisnel, C. Brigaudeau, Y. Bekro, Janat Mamybékova, O. Mignen","doi":"10.3390/ECMC-4-05618","DOIUrl":"https://doi.org/10.3390/ECMC-4-05618","url":null,"abstract":"The racemic synthesis in four steps of pyrazole SKF-96365 analogues without substituent (CF3 group) on the pyrazole platform was realized in moderate to good yields. The separation of (±) hydroxyl enantiomers 4 was developed successfully using the method of \"half-concentration\" with commercial (+)-(1S)- and (-)-(1R)-10-camphorsulfonic acid (CSA) followed by neutralization of diastereomers with MeONa in dry MeOH solution. With the pure enantiomers (-)-(1S)-4b and (+)-(1R)-4b, initial attempts to obtain the crystallized (-)-(1S)-7d and (+)-(1R)-7d after treatment of intermediate 6d with a solution of 1M HCl (for precipitation of hydrochloride salt 7d) failed. We have also investigated the effects of compounds 7(a-d) on endoplasmic reticulum (ER) Ca2+ and SOCE on PLP-B lymphocyte cell line and compound 7d was identified as a better SOCE inhibitor than SKF-96365. This preliminary SAR study showed that the MeO group in para-position of the phenethyl-1H-pyrazolium skeleton or for the Cbeta-phenylpropoxy side chain of 7 influenced the SOCE activity.","PeriodicalId":20450,"journal":{"name":"Proceedings of 4th International Electronic Conference on Medicinal Chemistry","volume":"35 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-11-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"75079483","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Kiran Gangarapu, Julakanti Venu, Mulagada Monja, T. Gouthami, V. Bakshi
Saquinavir mesylate (SQM) is subjected to forced degradation under conditions of hydrolysis, oxidation, dry heat, photolysis as recommended by International conference on Harmonization guideline Q1A (R2). In total, (I-V) degradation products (DPs) were formed in acidic hydrolytic, alkaline hydrolytic and oxidative conditions. Successful separation of SQM and its DPs was achieved on C18(4.6mm×75mm) 3.5μg column at ambient temperature (30 ̊C) with mobile phase A (10mM ammonium acetate in water), B100% acetonitrile at 2.0ml/min flow rate in the gradient mode. The injection volume was fixed at 20μl and detection wavelength at 238nm. The HPLC method was found to be linear, accurate, precise, sensitive, specific, rugged, and robust for quantification of SQM as well as degradation products. The major degradation products (DP-1) formed in hydrolytic acid conditions was identified and characterized by LC-MS/MS and proposed the fragmentation patterns by comparing with SQM. Further, DP-1 were isolated through column chromatography and analyzed by 1H NMR. In Silico molecular docking studies on HIV protease (PDB: 4qgi) for DPs and SQM was estimated and found to be pharmacologically inactive than SQM. Prediction of Toxicity and ADME properities were performed for DP-1 and SQM and found to less toxic.
{"title":"Identification of degradation products of saquinavir mesylate by LC-MS: Molecular docking and in silico ADME prediction studies","authors":"Kiran Gangarapu, Julakanti Venu, Mulagada Monja, T. Gouthami, V. Bakshi","doi":"10.3390/ecmc-4-05627","DOIUrl":"https://doi.org/10.3390/ecmc-4-05627","url":null,"abstract":"Saquinavir mesylate (SQM) is subjected to forced degradation under conditions of hydrolysis, oxidation, dry heat, photolysis as recommended by International conference on Harmonization guideline Q1A (R2). In total, (I-V) degradation products (DPs) were formed in acidic hydrolytic, alkaline hydrolytic and oxidative conditions. Successful separation of SQM and its DPs was achieved on C18(4.6mm×75mm) 3.5μg column at ambient temperature (30 ̊C) with mobile phase A (10mM ammonium acetate in water), B100% acetonitrile at 2.0ml/min flow rate in the gradient mode. The injection volume was fixed at 20μl and detection wavelength at 238nm. The HPLC method was found to be linear, accurate, precise, sensitive, specific, rugged, and robust for quantification of SQM as well as degradation products. The major degradation products (DP-1) formed in hydrolytic acid conditions was identified and characterized by LC-MS/MS and proposed the fragmentation patterns by comparing with SQM. Further, DP-1 were isolated through column chromatography and analyzed by 1H NMR. In Silico molecular docking studies on HIV protease (PDB: 4qgi) for DPs and SQM was estimated and found to be pharmacologically inactive than SQM. Prediction of Toxicity and ADME properities were performed for DP-1 and SQM and found to less toxic.","PeriodicalId":20450,"journal":{"name":"Proceedings of 4th International Electronic Conference on Medicinal Chemistry","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-11-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"83573452","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Margarida Espadinha, Jorge Dourado, Rocío Lajarín-Cuesta, Clara Herrera Arozamena, Lídia M D Gonçalves, João A Lopes, M. I. Rodríguez-Franco, D. J. V. A. Santos, C. Ríos, Maria M. M. Santos
The family of ionotropic glutamate receptors (iGluRs) is localized in the cell membrane of neurons and has crucial roles in the normal development of the central nervous system (CNS). Sustain healthy memory, learning, and cognitive processes are fundamental functions of these receptors. [1] N-Methyl-D-aspartate (NMDA) receptors belong to the family of iGluRs and its over-activation is associated to neuronal loss and, consequently, to major neurological disorders such as Parkinson and Alzheimer’s diseases. Recently, targeting the NMDA receptor was considered a promising strategy in the medicinal chemistry field and the development of effective NMDA receptor antagonists become an attractive therapeutic approach. [2] In the last years, Santos’ group has been involved in the design and development of potent NMDA receptor antagonists, more precisely enantiopure bicyclic lactams. [3-5] To evaluate the activity of the potential NMDA receptor antagonists, was measured their capacity to inhibit NMDA-induced increase of intracellular Ca2+ levels in in vitro cultures of embryonary rat cortical neurons, using the Ca2+-sensitive fluorescent dye Fluo-4. The first molecule that showed some interesting results was a (S)-phenylalaninol oxazolopyrrolidone. [3] After, based on the oxazolopyrrolidone scaffold, a hit-to-lead optimization was carried out in the search for more potent NMDA receptor antagonists. A new library of enantiopure phenylalaninol bicyclic lactams was developed and most of the new compounds displayed NMDA receptor antagonism. It was even more interesting the significant difference in activities between the two enantiomers. The most promising compound showed an IC50 value of 27 μM, on the same order of magnitude as that of memantine (47 μM), an NMDA receptor antagonist in clinical use for the treatment of Alzheimer’s disease. [5] More recently, we also extended our interest to more rigid molecules, also containing a bicyclic lactam core. Interestingly, this new family of compounds showed to be even more potent as NMDA receptor antagonists (4-fold more active than memantine). Additional biological tests indicated that the promising compounds can cross the blood-brain barrier (determined by an in vitro assay) and non-hepatotoxic, as well. Furthermore, the synthesis of the interesting aminoalchool-based libraries is easy to perform, resulting in moderate to good yields, and excellent stereoselectivities.
嗜离子性谷氨酸受体(iGluRs)家族定位于神经元细胞膜,在中枢神经系统(CNS)的正常发育中起着至关重要的作用。维持健康的记忆、学习和认知过程是这些受体的基本功能。[1] n -甲基- d -天冬氨酸(NMDA)受体属于iGluRs家族,其过度激活与神经元丢失有关,因此与帕金森病和阿尔茨海默病等主要神经系统疾病有关。近年来,靶向NMDA受体被认为是药物化学领域一种很有前途的策略,开发有效的NMDA受体拮抗剂成为一种有吸引力的治疗方法。[2]在过去的几年中,Santos的团队参与了有效的NMDA受体拮抗剂的设计和开发,更确切地说,是对不纯双环内酰胺。[3-5]为了评估潜在的NMDA受体拮抗剂的活性,在体外培养的胚胎大鼠皮质神经元中,使用Ca2+敏感荧光染料Fluo-4,测量了它们抑制NMDA诱导的细胞内Ca2+水平升高的能力。第一个显示出一些有趣结果的分子是(S)-苯丙醇恶唑吡咯烷酮。[3]之后,基于恶唑吡咯烷酮支架,进行了靶向先导优化,以寻找更有效的NMDA受体拮抗剂。建立了一个新的对异构苯丙醇双环内酰胺类化合物文库,大多数新化合物具有NMDA受体拮抗作用。更有趣的是,两种对映体在活性上的显著差异。最有希望的化合物的IC50值为27 μM,与临床用于治疗阿尔茨海默病的NMDA受体拮抗剂美金刚(47 μM)的IC50值相同。[5]最近,我们还将研究兴趣扩展到更刚性的分子,也含有双环内酰胺核。有趣的是,这个新的化合物家族显示出更有效的NMDA受体拮抗剂(活性比美金刚高4倍)。另外的生物学试验表明,这些有希望的化合物可以穿过血脑屏障(通过体外试验确定),而且没有肝毒性。此外,有趣的氨基醇类化合物库易于合成,产率中等至较高,具有良好的立体选择性。
{"title":"Bicyclic lactams as potential inhibitors of the NMDA receptor","authors":"Margarida Espadinha, Jorge Dourado, Rocío Lajarín-Cuesta, Clara Herrera Arozamena, Lídia M D Gonçalves, João A Lopes, M. I. Rodríguez-Franco, D. J. V. A. Santos, C. Ríos, Maria M. M. Santos","doi":"10.3390/ecmc-4-05631","DOIUrl":"https://doi.org/10.3390/ecmc-4-05631","url":null,"abstract":"The family of ionotropic glutamate receptors (iGluRs) is localized in the cell membrane of neurons and has crucial roles in the normal development of the central nervous system (CNS). Sustain healthy memory, learning, and cognitive processes are fundamental functions of these receptors. [1] N-Methyl-D-aspartate (NMDA) receptors belong to the family of iGluRs and its over-activation is associated to neuronal loss and, consequently, to major neurological disorders such as Parkinson and Alzheimer’s diseases. Recently, targeting the NMDA receptor was considered a promising strategy in the medicinal chemistry field and the development of effective NMDA receptor antagonists become an attractive therapeutic approach. [2] In the last years, Santos’ group has been involved in the design and development of potent NMDA receptor antagonists, more precisely enantiopure bicyclic lactams. [3-5] To evaluate the activity of the potential NMDA receptor antagonists, was measured their capacity to inhibit NMDA-induced increase of intracellular Ca2+ levels in in vitro cultures of embryonary rat cortical neurons, using the Ca2+-sensitive fluorescent dye Fluo-4. The first molecule that showed some interesting results was a (S)-phenylalaninol oxazolopyrrolidone. [3] After, based on the oxazolopyrrolidone scaffold, a hit-to-lead optimization was carried out in the search for more potent NMDA receptor antagonists. A new library of enantiopure phenylalaninol bicyclic lactams was developed and most of the new compounds displayed NMDA receptor antagonism. It was even more interesting the significant difference in activities between the two enantiomers. The most promising compound showed an IC50 value of 27 μM, on the same order of magnitude as that of memantine (47 μM), an NMDA receptor antagonist in clinical use for the treatment of Alzheimer’s disease. [5] More recently, we also extended our interest to more rigid molecules, also containing a bicyclic lactam core. Interestingly, this new family of compounds showed to be even more potent as NMDA receptor antagonists (4-fold more active than memantine). Additional biological tests indicated that the promising compounds can cross the blood-brain barrier (determined by an in vitro assay) and non-hepatotoxic, as well. Furthermore, the synthesis of the interesting aminoalchool-based libraries is easy to perform, resulting in moderate to good yields, and excellent stereoselectivities.","PeriodicalId":20450,"journal":{"name":"Proceedings of 4th International Electronic Conference on Medicinal Chemistry","volume":"46 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-11-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"77592577","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Valentina Barcherini, Margarida Espadinha, J. Soares, S. Gomes, A. Antunes, L. Saraíva, Maria J. Santos
Cancer is a group of diseases that can affect any part of the body via an uncontrolled and anomalous cellular proliferation. In this research field, the tumor protein p53 is a widely-studied therapeutic target in cancer treatment, as this transcription factor is inactivated in all types of human cancers. In 50% of malignancies, p53 is found expressed in its wild-type form and generally inhibited by two major negative regulators, MDM2 and MDMX. In the remaining 50% of cases, p53 is inactivated by contact and conformational mutations principally on its DNA-binding site, thus not exercising its regulatory function. [1] In the last years, our research group has been actively involved in the synthesis of small molecules to reactivate the p53 pathway. Starting from the enantiopure aminoalcohol tryptophanol, we have recently developed several small molecules that reactivate p53 (Figure 1). Here we present our most updated results on the development of a chemical library of (S)- and (R)-tryptophanol-derived oxazoloisoindolinones. This class of compounds may be accessed by cyclocondensation reaction of enantiopure forms of tryptophanol and several achiral oxoacids. In this synthetic approach, the chiral inductor (tryptophanol) is responsible for the stereo-outcome of the final product and it is part of the main skeleton of the bioactive molecules. For those reasons, this asymmetric reaction is highly efficient/atom economic. Interestingly, this specific one-step synthetic strategy allows to the construction of a new chiral center. [2] From this work tryptophanol-derived bicyclic lactams SLMP53-1 and DIMP53-1 were identified as the most promising p53 reactivators. [3] Further hit-to-lead optimization is ongoing, and assessment of the antiproliferative activity of the optimized oxazoloisoindolinones against four different cancer cells lines highlights that this chemical family displays selectively potent antitumor activity towards p53 with no apparent toxic effects. Acknowledgements Fundacao para a Ciencia e a Tecnologia (FCT) through PTDC/DTP-FTO/1981/2014, PTDC/QUI-QOR/29664/2017, UID/DTP/04138/2013, PD/BI/135334/2017 and IF/00732/2013. References [1]. Espadinha M, Barcherini V, Lopes E A, Santos M M M (2018). Curr Top Med Chem 18: 647-60. [2]. Dourado J, Perez M, Griera R, Santos M M M (2016). RSC, Chapter 3.1.19, 198-201. [3]. a) Soares J, Raimundo L, Pereira N A L, Monteiro A, Gomes S, Bessa C, Pereira C, Queiroz G, Bisio A, Fernandes J, Gomes C, Reis F, Goncalves J, Inga A, Santos M M M, Saraiva L (2016). Oncotarget 7(4): 4326-43; b) Soares J, Espadinha M, Raimundo L, Ramos H, Gomes A S, Gomes S, Loureiro J B, Inga A, Reis F, Gomes C, Santos M M M, Saraiva L (2017). Molecular Oncology 11(6): 612-27.
癌症是一组可以通过不受控制和异常的细胞增殖影响身体任何部位的疾病。在这个研究领域,肿瘤蛋白p53是一个被广泛研究的癌症治疗靶点,因为这种转录因子在所有类型的人类癌症中都是失活的。在50%的恶性肿瘤中,p53以野生型形式表达,通常被两种主要的负调节因子MDM2和MDMX抑制。在其余50%的病例中,p53主要是由于其dna结合位点的接触和构象突变而失活,因此无法发挥其调节功能。[1]在过去的几年里,我们课题组一直积极参与小分子的合成以重新激活p53通路。从对映纯氨基色氨酸开始,我们最近开发了几种可以重新激活p53的小分子(图1)。在这里,我们展示了我们关于(S)-和(R)-色氨酸衍生的恶唑异吲哚酮化学文库开发的最新结果。这类化合物可以通过色氨酸和几种非手性氧酸的对映纯形式的环缩合反应得到。在这种合成方法中,手性诱导剂(色氨酸)负责最终产物的立体产物,它是生物活性分子主要骨架的一部分。由于这些原因,这种不对称反应是非常高效的/原子经济的。有趣的是,这种特定的一步合成策略允许构建新的手性中心。[2]从这项工作中,色氨酸衍生的双环内酰胺SLMP53-1和DIMP53-1被确定为最有希望的p53再激活剂。[3]进一步的hit-to-lead优化正在进行中,对优化后的恶唑异吲哚酮对四种不同癌细胞系的抗增殖活性的评估表明,该化学家族对p53表现出选择性的有效抗肿瘤活性,没有明显的毒性作用。致谢:科学与技术基金(FCT)通过PTDC/DTP- fto /1981/2014、PTDC/QUI-QOR/29664/2017、UID/DTP/04138/2013、PD/BI/135334/2017和IF/00732/2013.文献[1]。Espadinha M, Barcherini V, Lopes E A, Santos M M M M M M(2018)。[2].中华医学杂志,18(2):647-60。Dourado J, Perez M, Griera R, Santos M M M M M(2016)。[3].中国科学院学报,vol . 31 (1), 198-201.]a) Soares J, Raimundo L, Pereira N a L, Monteiro a, Gomes S, Bessa C, Pereira C, Queiroz G, Bisio a, Fernandes J, Gomes C, Reis F, Goncalves J, Inga a, Santos M M M M, Saraiva L(2016)。Oncotarget 7(4): 4326-43;b) Soares J, Espadinha M, Raimundo L, Ramos H, Gomes A S, Gomes S, Loureiro J b, Inga A, Reis F, Gomes C, Santos M M M M, Saraiva L(2017)。中国生物医学工程学报(英文版),11(6):626 - 629。
{"title":"Enantiopure oxazoloisoindolinones: Promising small molecules for p53-based therapy with potential anticancer properties","authors":"Valentina Barcherini, Margarida Espadinha, J. Soares, S. Gomes, A. Antunes, L. Saraíva, Maria J. Santos","doi":"10.3390/ECMC-4-05630","DOIUrl":"https://doi.org/10.3390/ECMC-4-05630","url":null,"abstract":"Cancer is a group of diseases that can affect any part of the body via an uncontrolled and anomalous cellular proliferation. In this research field, the tumor protein p53 is a widely-studied therapeutic target in cancer treatment, as this transcription factor is inactivated in all types of human cancers. In 50% of malignancies, p53 is found expressed in its wild-type form and generally inhibited by two major negative regulators, MDM2 and MDMX. In the remaining 50% of cases, p53 is inactivated by contact and conformational mutations principally on its DNA-binding site, thus not exercising its regulatory function. [1] In the last years, our research group has been actively involved in the synthesis of small molecules to reactivate the p53 pathway. Starting from the enantiopure aminoalcohol tryptophanol, we have recently developed several small molecules that reactivate p53 (Figure 1). Here we present our most updated results on the development of a chemical library of (S)- and (R)-tryptophanol-derived oxazoloisoindolinones. This class of compounds may be accessed by cyclocondensation reaction of enantiopure forms of tryptophanol and several achiral oxoacids. In this synthetic approach, the chiral inductor (tryptophanol) is responsible for the stereo-outcome of the final product and it is part of the main skeleton of the bioactive molecules. For those reasons, this asymmetric reaction is highly efficient/atom economic. Interestingly, this specific one-step synthetic strategy allows to the construction of a new chiral center. [2] From this work tryptophanol-derived bicyclic lactams SLMP53-1 and DIMP53-1 were identified as the most promising p53 reactivators. [3] Further hit-to-lead optimization is ongoing, and assessment of the antiproliferative activity of the optimized oxazoloisoindolinones against four different cancer cells lines highlights that this chemical family displays selectively potent antitumor activity towards p53 with no apparent toxic effects.\u0000Acknowledgements\u0000Fundacao para a Ciencia e a Tecnologia (FCT) through PTDC/DTP-FTO/1981/2014, PTDC/QUI-QOR/29664/2017, UID/DTP/04138/2013, PD/BI/135334/2017 and IF/00732/2013.\u0000References\u0000[1]. Espadinha M, Barcherini V, Lopes E A, Santos M M M (2018). Curr Top Med Chem 18: 647-60.\u0000[2]. Dourado J, Perez M, Griera R, Santos M M M (2016). RSC, Chapter 3.1.19, 198-201.\u0000[3]. a) Soares J, Raimundo L, Pereira N A L, Monteiro A, Gomes S, Bessa C, Pereira C, Queiroz G, Bisio A, Fernandes J, Gomes C, Reis F, Goncalves J, Inga A, Santos M M M, Saraiva L (2016). Oncotarget 7(4): 4326-43; b) Soares J, Espadinha M, Raimundo L, Ramos H, Gomes A S, Gomes S, Loureiro J B, Inga A, Reis F, Gomes C, Santos M M M, Saraiva L (2017). Molecular Oncology 11(6): 612-27.","PeriodicalId":20450,"journal":{"name":"Proceedings of 4th International Electronic Conference on Medicinal Chemistry","volume":"82 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-11-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"79960597","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Ever since their discovery, hydantoins have attracted huge attention due to their intriguing properties, vast chemical diversity and potential, as well as their broad spectra of biological activity. The wide set of their biological activity includes antimicrobial, antitumor, antiandrogen, anticonvulsant, antiteratogenic activity, etc. They are also used in the treatment of cachexia, psoriasis, wounds in general and also as muscle relaxants. There are many synthetic routes to hydantoins and some of them involve amino acids. As rigorous chemical conditions are not required, these reactions can be manifested in physiological conditions too, especially in the cases when protein consumption is increased and thus hydantoins have been isolated from urine. With all this in mind, elucidation of biological implications of hydantoins gains importance. In this study, an amino acid derived 2-thiohydantoin, 5[2-(methylthio)ethyl]3-(2propen1yl)2-thioxo-4imidazolidinone, has been synthesized and fully characterized by NMR and IR spectroscopy, as well as X-ray crystallography. An extensive antimicrobial study has been carried out on ten bacterial isolates (Grampositive and Gram-negative), as well as on five fungal isolates. Cytotoxicity has been tested on the cell lines of the normal lung fibroblasts, as well as breast, colon and lung tumor cell lines. Ultimately, a fish embryo toxicity (FET) assay has been carried out in vivo on the zebrafish model, testing for lethal and teratogenic effects and cardiotoxicity. Based on the found biological activity in previously mentioned assays, a determination of therapeutic potential has been carried out to show whether the compound is toxic in antimicrobial and anticancer doses.
{"title":"Synthesis, characterization and an extensive biological evaluation of 5-[2-(methylthio)ethyl]-3-(2-propen-1-yl)-2-thioxo-4-imidazolidinone","authors":"Biljana M Šmit, P. Stanić, Marijana Zivkovic","doi":"10.3390/ecmc-4-05625","DOIUrl":"https://doi.org/10.3390/ecmc-4-05625","url":null,"abstract":"Ever since their discovery, hydantoins have attracted huge attention due to their intriguing properties, vast chemical diversity and potential, as well as their broad spectra of biological activity. The wide set of their biological activity includes antimicrobial, antitumor, antiandrogen, anticonvulsant, antiteratogenic activity, etc. They are also used in the treatment of cachexia, psoriasis, wounds in general and also as muscle relaxants. There are many synthetic routes to hydantoins and some of them involve amino acids. As rigorous chemical conditions are not required, these reactions can be manifested in physiological conditions too, especially in the cases when protein consumption is increased and thus hydantoins have been isolated from urine. With all this in mind, elucidation of biological implications of hydantoins gains importance. In this study, an amino acid derived 2-thiohydantoin, 5[2-(methylthio)ethyl]3-(2propen1yl)2-thioxo-4imidazolidinone, has been synthesized and fully characterized by NMR and IR spectroscopy, as well as X-ray crystallography. An extensive antimicrobial study has been carried out on ten bacterial isolates (Grampositive and Gram-negative), as well as on five fungal isolates. Cytotoxicity has been tested on the cell lines of the normal lung fibroblasts, as well as breast, colon and lung tumor cell lines. Ultimately, a fish embryo toxicity (FET) assay has been carried out in vivo on the zebrafish model, testing for lethal and teratogenic effects and cardiotoxicity. Based on the found biological activity in previously mentioned assays, a determination of therapeutic potential has been carried out to show whether the compound is toxic in antimicrobial and anticancer doses.","PeriodicalId":20450,"journal":{"name":"Proceedings of 4th International Electronic Conference on Medicinal Chemistry","volume":"9 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-11-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"82427315","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"New multifunctional diamine AGE/ALE inhibitors to prevent oxidative and carbonyl stress exacerbation in Alzheimer's disease","authors":"Elodie Lohou, N. Sasaki, A. Boullier, P. Sonnet","doi":"10.3390/ECMC-4-05622","DOIUrl":"https://doi.org/10.3390/ECMC-4-05622","url":null,"abstract":"","PeriodicalId":20450,"journal":{"name":"Proceedings of 4th International Electronic Conference on Medicinal Chemistry","volume":"110 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-11-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"87608932","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
T. Marchyshak, Z. Tkachuk, L. Semernikova, T. Yakovenko
{"title":"Hepatoprotective and antioxidant effects of oligoribonucleotides-D-mannitol complexes against thioacetamide-induced liver fibrosis","authors":"T. Marchyshak, Z. Tkachuk, L. Semernikova, T. Yakovenko","doi":"10.3390/ecmc-4-05624","DOIUrl":"https://doi.org/10.3390/ecmc-4-05624","url":null,"abstract":"","PeriodicalId":20450,"journal":{"name":"Proceedings of 4th International Electronic Conference on Medicinal Chemistry","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-11-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"81186174","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}